Korean J Urol.  2007 Apr;48(4):416-421. 10.4111/kju.2007.48.4.416.

The Effect of Transrectal Ultrasound Guided Prostate Biopsies on Erectile Function

• Sim YJ
• Park HJ

• KMID: 1997109
• DOI: http://doi.org/10.4111/kju.2007.48.4.416

Abstract

PURPOSE
The aim of this study was to assess the effects of prostate biopsies on erectile dysfunction.
MATERIALS AND METHODS
Thirty nine patients who underwent transrectal ultrasonography (TRUS)-guided prostate biopsy between March 2006 and September 2006 were prospectively studied. Erectile dysfunction (ED) was assessed by using the self-administered International Index of Erectile Function (IIEF)-5 at the day of biopsy, and at 1 and 3 months later. The concomitant ED-related systemic disease and medications were recorded. The severity of ED was classified into 5 categories.
RESULTS
The patients' mean age was 57.6 years (range: 32-74). The median IIEF-5 scores at biopsy and at 1 month and 3 months after biopsy were 15.6, 14.9 and 15.1, respectively (p>0.05). At the day of the biopsies, ED was reported by 28 patients (71.79%). Concomitant ED-related systemic disease and/or the use of medications were recorded for 18 patients (46.0%). One month and 3 months after biopsies, ED was reported for 31 (79.48%) and 30 (76.92%) patients, respectively. At 1 and 3 months later, 3 previously potent (7.69%) patients and 2 previously potent (5.13%) patients reported erectile dysfunction, respectively.
CONCLUSIONS
TRUS-guided prostate biopsy did not statistically affect erectile dysfunction. Even so, a prospective analysis with more patients is needed and the risk of acute erectile dysfunction should be discussed with the patients undergoing TRUS.

Keyword

Prostate; Biopsy; Erectile dysfunction

MeSH Terms

Biopsy*
Erectile Dysfunction
Humans
Male
Prospective Studies
Prostate*
Ultrasonography*

Reference

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000. 50:7–33.

2. Chodak G. Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol. 2006. 8:Suppl 2. S3–S8.

3. 2001 Annual report of the Korea central cancer registry (based on registered data from 134 hospitals). 2003. Korea central cancer registry, ministry of health and welfare republic of Korea.

4. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989. 142:71–74.

5. Son HC, Byun SS, Park EC, Cho KS, Jo MK, Kim SW, et al. Prevalence of sexual dysfunction in men older than 40 living in Seoul: epidemiologic survey using questionnaire. Korean J Urol. 2002. 43:52–61.

6. Derouet H, Osterhage J, Sittinger H. Erectile dysfunction. Epidemiology, physiology, etiology, diagnosis and therapy. Urologe A. 2004. 43:197–207.

7. Penson DF, Latini DM, Lubeck DP, Wallace K, Henning JM, Lue T. Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Result from the ExCEED data base. J Urol. 2003. 169:1458–1461.

8. Meyer JP, Gillatt DA, Lockyer R, Macdonagh R. The effect of erectile dysfunction on the quality of life of men after radical prostatectomy. BJU Int. 2003. 92:929–931.

9. Penson DF. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. Rev Urol. 2001. 3:113–119.

10. Cha JS, Park JK. Association between lower urinary tract symptoms and erectile dysfunction. Korean J Urol. 2005. 46:1023–1027.

11. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001. 166:856–860.

12. Rhoden EL, Teloken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002. 14:245–250.

13. Ahn TY, Lee DS, Kang WC, Hong JH, Kim YS. Validation of an abridged Korean version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Korean J Urol. 2001. 42:535–540.

14. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999. 11:319–326.

15. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002. 60:826–830.

16. Rietbergen JB, Kruger AE, Kranse R, Schroder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology. 1997. 49:875–880.

17. Zisman A, Leibovici D, Kleinmann J, Cooper A, Siegel Y, Lindner A. The impact of prostate biopsy on patient wellbeing: a prospective study of voiding impairment. J Urol. 2001. 166:2242–2246.

18. Chrisofos M, Papatsoris AG, Dellis A, Varkarakis IM, Skolarikos A, Deliveliotis C. Can prostate biopsies affect erectile function? Andrologia. 2006. 38:79–83.

19. Deliveliotis C, Liakouras C, Delis A, Skolarikos A, Varkarakis J, Protogerou V. Prostate operations: long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population. Urol Res. 2004. 32:283–289.

20. Rosen RC, Riley A, Wagner G, Osterloch IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997. 49:822–830.

21. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology. 1999. 54:346–351.

22. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, Mckinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000. 163:460–463.

23. Rosen RC, Wing R, Schneider S, Gendrano N 3rd. Epidemiology of erectile dysfunction: the role of medical comorbidities and lifestyle factors. Urol Clin North Am. 2005. 32:403–417.

24. Aytac IA, Araujo AB, Johannes CB, Kleinman KP, McKinlay JB. Socioeconomic factors and incidence of erectile dysfunction: findings of the longitudinal Massachussetts Male Aging Study. Soc Sci Med. 2000. 51:771–778.